Slide 1: Investor Presentation: Annual Financial Results FY22
For personal use only INVESTOR PRESENTATION Annual Financial Results Full year ended 30 June 2022 24 August 2022 REPLACE WITH ALTERNATIVE (MORE MODERN) WAREHOUSE IMAGE IN THIS SQUARE
Slide 2: Disclaimer
DISCLAIMER For personal use only The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and, to the extent permitted by law, no repres
Slide 3: EBOS Group Limited
Hor personal tHe pohly GROUP LIMITED
Slide 4: Group Financial Results
For personal use only GROUP FINANCIAL RESULTS 4
Slide 5: FY22 Summary Results
FY22 SUMMARY RESULTS EBOS’ strong performance has continued with revenue exceeding $10 billion for the first time For personal use only $m Underlying1 Var Statutory Var Revenue 10,734 16.6% 10,734 16.6% EBITDA 436.8 19.0% 405.8 11.7% EBIT 355.0 20.5% 323.9 11.5% NPAT 228.2 21.3% 202.6 9.3% EPS (cent
Slide 6: Key Highlights
KEY HIGHLIGHTS Continued strong organic growth in Healthcare and Animal Care and investing for future growth For personal use only Healthcare • Healthcare’s strong performance was driven by our Community Pharmacy, TerryWhite Chemmart (“TWC”), EBIT up 24.0%1 Institutional Healthcare and Contract Logi
Slide 7: Key Highlights (Cont.)
KEY HIGHLIGHTS (CONT.) COVID-19 and inflation have had various impacts on the Group For personal use only COVID-19 • The effects of COVID-19 continue to impact our various Group businesses both positively and negatively. Overall, impacts we estimate that the net impact of COVID-19 has been positive
Slide 8: Business and Segment Performance
BUSINESS AND SEGMENT PERFORMANCE Our Healthcare and Animal Care businesses contributed positively to strong earnings growth, with For personal use only Institutional Healthcare a highlight GOR bridge ($m) Underlying EBIT bridge ($m) FY22 growth 14.0% 47.8% 40.2% 14.8% 25.3% 24.0% 15.3% (44.3%) 20.5%
Slide 9: Acquisitions
ACQUISITIONS EBOS completed five acquisitions this year, including the acquisition of LifeHealthcare and a small medical For personal use only consumables distribution business in H2 FY22 LifeHealthcare update • The acquisition was completed on 31 May 2022. • EBOS is now one of the largest independe
Slide 10: Continued Investing for Growth
CONTINUED INVESTING FOR GROWTH We continue to expand and invest in our operational infrastructure to support our growth For personal use only Project Location Status Segment / Division Construction and New pet food manufacturing Parkes commissioning Animal Care facility completed New medical consuma
Slide 11: Sustainability
SUSTAINABILITY EBOS’ 2022 Sustainability Report highlights key initiatives that we are prioritising For personal use only 11 Note 1: Milestone dates exclude LifeHealthcare, Transmedic and Australian Biotechnologies.
Slide 12: Group Performance
GROUP PERFORMANCE $m FY22 FY21 Var Var% For personal use only Underlying Results • Revenue of $10,734.1m, an increase of $1,531.2m or Revenue 10,734.1 9,202.9 1,531.2 16.6% 16.6%: GOR 1,233.8 984.3 249.5 25.3% o Healthcare up 17.1%; EBITDA 436.8 367.1 69.7 19.0% o Animal Care up 8.8%. Depreciation &
Slide 13: Long Term Track Record
LONG TERM TRACK RECORD EBOS has delivered consistent financial performance over the long term For personal use only Underlying EBIT ($m) Underlying EPS ($ cents per share) DPS (NZ$ cents per share) 12.5% CAGR 10.8% CAGR 11.2% CAGR 355 96 129 89 295 115 78 263 101 69 72 230 90 94 63 218 86 59 204 77
Slide 14: Healthcare Results
14 For personal use only RESULTS HEALTHCARE
Slide 15: Healthcare Segment
HEALTHCARE SEGMENT Healthcare segment generated revenue of $10.2b representing growth of 17.1% For personal use only $m FY22 FY21 Var$ Var% • The performance of our Healthcare segment reflects strong organic growth supplemented by the completion of five Revenue 10,192.8 8,705.4 1,487.4 17.1% acquisi
Slide 16: Community Pharmacy
COMMUNITY PHARMACY For personal use only • Revenue increased by $1,051.7m (19.5%) and GOR increased by $m FY22 FY21 Var$ Var% $69.6m (14.0%), benefitting from: Revenue 6,441.7 5,390.0 1,051.7 19.5% o Customer and market share growth; GOR 568.7 499.1 69.6 14.0% o Strong performance from our community
Slide 17: TerryWhite Chemmart
TerryWhite Chemmart that’s real chemistry For personal use only • TWC added 51 new network partners to its national network in FY22, continuing its Network sales growth in FY222 impressive growth in pharmacy numbers and growing the network to over 500 stores. • TWC is now ranked second overall from
Slide 18: Institutional Healthcare
INSTITUTIONAL HEALTHCARE For personal use only • Institutional Healthcare revenue increased by $383.5m (14.3%) and GOR increased by $122.4m (47.8%) largely from increases in $m FY22 FY21 Var$ Var% sales of new specialty medicines combined with strong organic Revenue 3,069.5 2,686.0 383.5 14.3% and i
Slide 19: Contract Logistics
CONTRACT LOGISTICS For personal use only • Contract Logistics revenue increased by $77.9m (9.7%) and GOR by $37.1m (40.2%), attributable to: $m FY22 FY21 Var$ Var% Revenue 885.5 807.5 77.9 9.7% o Growth in Australia via increased market share; and GOR 129.4 92.3 37.1 40.2% o Growth in New Zealand fr
Slide 20: Animal Care Results
20 For personal use only CARE ANIMAL RESULTS
Slide 21: Animal Care Segment
ANIMAL CARE SEGMENT Animal Care has continued to capitalise on strong pet market conditions For personal use only • Animal Care revenue increased by $43.8m (8.8%) and EBIT $m FY22 FY21 Var$ Var% increased by $9.6m (15.3%) due to strong performances from our Revenue 541.3 497.5 43.8 8.8% leading bran
Slide 22: Continued Product and Brand Growth
CONTINUED PRODUCT AND BRAND GROWTH Our key brands demonstrated solid growth For personal use only FY22 Sales Categories Sales growth drivers growth1 • Strong consumer support for our products. • Continued investment in marketing to drive increased brand awareness and Black Hawk 18.2% retail support.
Slide 23: Financial Information and Outlook
For personal use only FINANCIAL INFORMATION AND OUTLOOK 23
Slide 24: Cash Flow
CASH FLOW For personal use only Underlying Cash from Operating Activities $m FY22 FY21 Var$ Var% ($m)1 Underlying EBITDA 436.8 367.1 69.7 19.0% Interest paid (28.7) (27.6) (1.1) Tax paid (115.3) (72.2) (43.2) Net working capital and other 302.2 291.0 (1.9) 34.8 (36.6) movements 231.8 Underlying Cash
Slide 25: Working Capital and ROCE
WORKING CAPITAL AND ROCE For personal use only Working Capital Return on Capital Employed (ROCE) $m FY22 FY21 FY20 Net Working Capital Trade receivables 1,278.1 1,098.9 984.6 18.0% 18.6% Inventory 1,120.1 784.8 737.7 17.1% 16.3% 15.9% Trade payables/other (1,996.7) (1,622.3) (1,417.2) Total 401.4 26
Slide 26: Net Debt and Maturity Profile
NET DEBT AND MATURITY PROFILE For personal use only Net Debt and Net Debt : EBITDA ratio Cash and Debt Maturity Profile 1.94x 1.74x 963 1.41x 192 1.11x 0.85x 517 860 345 772 250 222 517 432 366 140 71 345 327 271 110 151 Jun-18 Jun-19 Jun-20 Jun-21 Jun-22 Cash on FY23 FY24 FY25 FY26 FY27 Hand Net De
Slide 27: Earnings and Dividends per Share
EARNINGS AND DIVIDENDS PER SHARE For personal use only Underlying Earnings per Share (A$ cents) Dividends per Share (NZ$ cents) H1 H2 H1 H2 129.0 114.9 96.0 88.5 100.8 90.4 94.2 77.5 62.4 68.5 71.5 57.2 49.0 46.0 46.4 49.5 40.0 44.4 35.5 37.0 57.8 66.6 47.0 46.0 47.8 51.3 34.5 37.5 42.5 33.0 FY18 FY
Slide 28: Outlook
OUTLOOK For personal use only • EBOS is pleased with the strong earnings growth in FY22 and we expect another year of profitable growth in FY23. • The Group’s portfolio of businesses has proven to be very resilient throughout the COVID-19 pandemic, however, given the global economic and geopolitical
Slide 29: Supporting Information
For personal use only SUPPORTING INFORMATION 29
Slide 30: Reconciliation of Statutory to Underlying Results
RECONCILIATION OF STATUTORY TO UNDERLYING RESULTS For personal use only FY22 FY21 $m EBITDA EBIT PBT NPAT EBITDA EBIT PBT NPAT Statutory result 405.8 323.9 295.3 202.6 363.3 290.7 263.0 185.3 Net transaction costs incurred on M&A 31.0 31.0 29.8 25.6 3.8 3.8 3.8 2.9 Underlying result 436.8 355.0 325.
Slide 31: Segment EBITDA and EBIT Reconciliation
SEGMENT EBITDA AND EBIT RECONCILIATION For personal use only EBITDA EBIT $m FY22 FY21 Var$ Var% FY22 FY21 Var$ Var% Healthcare Statutory 358.5 316.2 42.3 13.4% 285.1 251.1 34.0 13.5% add One-off items 31.0 3.8 27.2 31.0 3.8 27.2 Underlying1 389.6 320.0 69.5 21.7% 316.2 254.9 61.2 24.0% Animal Care S
Slide 32: Glossary of Terms and Measures
GLOSSARY OF TERMS AND MEASURES Except where noted, common terms and measures used in this document are based upon the following For personal use only definitions: Term Definition Revenue Revenue from the sale of goods and the rendering of services. Gross Operating Revenue (GOR) Revenue less cost of
Slide 33: EBOS Group Limited
Hor personal tse only GROUP LIMITED